Journal of Clinical Research

Clinical education is an essential component of medical training, providing students with the opportunity to apply their knowledge and skills in a real-world setting. However, the traditional model of clinical education has been criticized for its reliance on passive learning and limited opportunities for students to engage in meaningful clinical experiences. A clinical education redesign is needed to address these challenges and create a more effective and engaging learning environment for medical students. The first step in a clinical education redesign is to move away from a passive learning model and towards an active learning model. This involves creating opportunities for students to engage in hands-on learning experiences, such as simulation exercises, case-based discussions, and small-group activities. These activities encourage students to apply their knowledge and skills in a practical context, and promote critical thinking, problem-solving, and teamwork. Another key element of a clinical education redesign is to provide students with a more personalized and flexible learning experience. This can be achieved through the use of technology, such as online learning platforms and mobile apps, which allow students to access educational resources and complete assignments at their own pace and on their own schedule. By providing students with greater flexibility and control over their learning, clinical education can become more engaging and effective.

About half of all cancers in humans have mutations in the tumor suppressor p53 (p53), most of which are missense mutations. Not only do p53 mutations impair its ability to suppress drugs, but they also give the missense mutant p53 (mutp53) oncogenic properties that are distinct from those of the wild-type p53. Restoring or stabilizing wtp53 conformation from mutp53, rescuing p53 nonsense mutations, depleting mutp53 proteins, and inducing p53 synthetic lethality or targeting vulnerabilities imposed by p53 deficiencies (activated retrotransposons) or mutations (enhanced YAP/TAZ) are some of the approaches that have been taken to develop novel cancer therapies because p53 mutations are specific to cancer. The mechanisms of action and activities of FDA-approved and clinically available drugs that target p53 mutations to stop the progression of cancer are summarized here Cancer spread is aided by mutations in the tumor suppressor p53 (p53).

Objectives: The efficacy and safety of NeuroAiD™ is well-established in patients with ischemic stroke in the acute and chronic phase. It is an addon treatment to standard therapies and there were no reports of major interactions. However, there is currently no data on the use of NeuroAiDTM in combination with anticoagulants. We aimed to determine the safety of using MLC901 (NeuroAiD II) with anticoagulants among patients in the Eastern European Cohort.

Methods: We performed a subgroup analysis of patients enrolled in the NeuroAiD Safe Treatment Registry (NeST). Patient who were given anticoagulants were included. Data collected were baseline demographics, diagnosis, concomitant medications and adverse events.

Results: A total of 98 patients were included. There were 48 female (49%), median age 64 years IQR (50,71), baseline median NIHSS 16, IQR (11,20), median mRS 4, IQR (3.25,5). Diagnoses included: Ischemic Stroke -80%, Traumatic Brain Injury - 7%, Cerebral Venous Thrombosis - 3%, Global hypoxic encephalopathy - (2%), Venous infarct - 1 %, AV Malformation - 1%, Meningoencephalitis - 1%. Risk factors were: hypertension - 72%, diabetes mellitus - 21% and hyperlipidaemia - 31%. The presence of cardiac disease was seen in 38% of which 24% had non-valvular atrial fibrillation. The concomitant anticoagulants were used in 98% of patients and included: low-molecular-weight heparin (LMWH), direct acting oral anticoagulants (DOACs), and Vitamin K antagonist (VKA). Neither adverse events nor side effects were reported.

Conclusions: The study provides new evidence for the safe use of MLC901 when combined with anticoagulants in a real-world setting.

Asthma is a chronic respiratory condition that affects millions of people worldwide. Effective management of asthma requires appropriate clinical practices, including the assessment of the quality of care. Quality assessment is the process of evaluating healthcare services to ensure that they meet established standards of quality. There are several approaches to assessing the quality of clinical practice in asthma management. One approach is to use evidence-based guidelines. These guidelines provide recommendations for the diagnosis and treatment of asthma based on the latest research and clinical experience. The use of evidence-based guidelines is an essential aspect of quality assessment since they are designed to ensure that patients receive appropriate care based on the latest scientific knowledge.